Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

No benefit for adjuvant durvalumab in completely resected NSCLC

Prof Glenwood Goss - University of Ottawa, Ottawa, Canada

No benefit for adjuvant durvalumab in completely resected NSCLC ( Prof Glenwood Goss - University of Ottawa, Ottawa, Canada )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Watchful waiting vs intravesical BCG in high grade pT1 bladder cancer

Dr Hiroshi Kitamura - University of Toyama, Toyama, Japan

Watchful waiting vs intravesical BCG in high grade pT1 bladder cancer ( Dr Hiroshi Kitamura - University of Toyama, Toyama, Japan )

Durvalumab and oleclumab boost for SBRT plus chemo in ER+/HER2- breast cancer

Dr Alex De Caluwe - Institut Jules Bordet, Brussels, Belgium

Durvalumab and oleclumab boost for SBRT plus chemo in ER+/HER2- breast cancer ( Dr Alex De Caluwe - Institut Jules Bordet, Brussels, Belgium )

Faecal microbiota transplantation increases activity of immunotherapy in mRCC

Dr Chiara Ciccarese - Fondazione Policlinico Universitario Agostino Gemelli...

Faecal microbiota transplantation increases activity of immunotherapy in mRCC ( Dr Chiara Ciccarese - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy )

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal...

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )

Novel antibody drug conjugate TORL-1-23 shows preliminary antitumour activity...

Prof Gottfried Konecny - University of California, Los Angeles, USA

Novel antibody drug conjugate TORL-1-23 shows preliminary antitumour activity in heavily-pretreated ovarian, endometrial, and testicular cancers ( Prof Gottfried Konecny - University of California, Los Angeles, USA )

Immunotherapy resistance pathways investigated to tailor combination NSCLC...

Prof Pascale Tomasini - Aix-Marseille University, Marseille, France

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy ( Prof Pascale Tomasini - Aix-Marseille University, Marseille, France )

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van...

ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )

Mutational-based treatment approach may significantly improve outcomes in...

Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )

Mirvetuximab soravtansine shows promise in FRα-positive, platinum-sensitive...

Dr Angeles Alvarez Secord - Duke Cancer Center, Durham, USA

Mirvetuximab soravtansine shows promise in FRα-positive, platinum-sensitive ovarian cancer ( Dr Angeles Alvarez Secord - Duke Cancer Center, Durham, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

More from ecancer